2015-05-012024-05-13https://scholars.lib.ntu.edu.tw/handle/123456789/648828摘要：為了促進臺灣的新藥發展與進步，此延續型計畫整合了臺大醫學院實驗動物中心(NTUMC-LAC)、藥物研究中心(NTU-DRC)與初級細胞培養實驗室之人才與資源，建立各種人類疾病動物模式或其他細胞藥理與毒理評估方法，以提供學術界或產業界在轉譯醫學研究及臨床前藥理與安全性評估之服務平台。以先前的研究成果為基礎，臺大醫學院實驗動物中心不僅持續提供在癌症、心血管疾病、糖尿病、神經性疾病，及感染症模式等詳盡的藥理評估，針對心臟安全性評估與non-GLP 毒性試驗也提供新的服務項目。為了對人類疾病和動物臨床檢驗提供更合適的疾病動物模式，我們與A4 核心設施合作發展新的技術，包括對特殊基因KO/KI 小鼠的基因操作技術。在未來的一年，此計畫將著重在與其他AM 計畫(AM1、AM3 和AM4)的服務項目整合，並針對心血管和神經模式、新的腫瘤模型 (PDX-NSG, CSC-model, drug-resistantmodel)、安全性與毒性評估 (hERG, human iPS-derived cardiomyocyte/MEA、沙門菌逆突變試驗、染色體結構異) 提供我們獨特與專業的知識和技術。此外，我們也提供其他的技術諮詢服務、合作研究與提供包括特殊品系動物凍胚與復育之繁殖服務。主要目標是協助有潛力之候選藥物進入臨床前試驗或轉譯醫學研究。我們期許這個優化與升級版的計畫，能持續地建立整合性實驗動物研究系統與藥物研究發展人才培育;提供產品導向之創新藥物與診斷試劑組所需之服務，並且努力發展新的技術或疾病模式，並優化服務的質與量，繼續針對研究人員與生技醫藥產業之需求提供服務，並加強產業價值。長期目標是促進生技製藥研究成果之國際化，建立國際合作網絡，並促成科學發現進入轉譯醫學與實際應用層面。<br> Abstract: To facilitate the new drug development and progress in Taiwan, our consecutiveproject integrate the talents and resource of the NTU Medical College Laboratory AnimalCenter (NTUMC-LAC) and NTU Drug Research Center (NTU-DRC), to establish a serviceplatform including animal models for human diseases and the cellular evaluation method forthe researchers or industry on translational medicine or pre-clinical studies onpharmacological and safety evaluation.Base on the previous achievements, NTUMC-LAC will not just continuously providecomprehensive pharmacological evaluation on cancers, cardiovascular diseases, diabetes,neurological disorders, and infection models, but also provide the new service items oncardiac safety evaluation and non-GLP toxicity tests. In order to provide more suitabledisease animal models for human diseases and the animal clinic examination, we collaboratewith A4 core to develop new techniques including the gene manipulation techniques(TALEN and CRISPR/Cas) on specific gene KO/KI mice.For the coming year, this project will focus on the integration of the service items withother AM projects (AM1, AM3, and AM4), and provide our unique and expertise on servingthe cases in cardiac and neurological models, new tumor models (PDX-NSG, CSC-model,drug-resistant model), safety and toxicity evaluations (hERG, human iPS-derivedcardiomyocyte/MEA, Ames test, chromosomal aberration test, micronuclei test, oral acuteand 28-day sub-acute toxicity tests). Besides, we also provide other technique-consultingservices, collaboration, and provide breeding services including cryopreservation andre-derivation of special strain animals. The major goal is to conduct the development of thepromising candidate products into preclinical test or translational research.This updated and upgraded project will continuously establish the integrated researchsystem and the cultivation of the manpower for the services in conducting product-orientedinnovating drugs or diagnostic kits, and trying to develop new techniques or disease modelsfor service; and optimize the service quantity and quality, continue providing the services forthe requirement of the researchers and biopharmaceuticals industry and to reinforce theindustry value chains. The long-term goal is to promote the internationalization ofbiopharmaceuticals research results, to establish the international cooperation web, and tocatalyze the scientific discoveries into translational medicine or practical application.人類疾病動物模式藥效評估藥物副作用基因轉殖血液生化檢測病理檢測毒 性試驗生技醫藥國家型科技計畫Human Disease Animal ModelDrug Efficacy EvaluationDrug Adverse Effects EvaluationGene ManipulationBlood Biochemistry ExaminationTissue Pathology ExaminationToxicity TestNRPB